Search:
Filter:
Post type:
Sort:
Victory Medical Center Pharmacy issued a voluntary recall for three lots of its compounded glutathione vials due to elevated endotoxin levels.
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
United States District Court District of New Jersey USA v Frank Incognito Judgment Filed July 2026 Read the document.
United States District Court District of New Jersey USA v Frank Incognito Plea Agreement Filed February 2026 Read the document.
United States District Court District of New Jersey USA v Frank Incognito Information Filed February 2026 Read the document.
United States District Court Western District of Virginia USA v Bryce Cleveland Plea Agreement Filed July 2026 Read the document.
United States District Court Western District of Virginia USA v Bryce Cleveland Indictment Filed July 2024 Read the document.
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”
FDA’s Pharmaceutical Compounding Advisory Committee voted to add six of seven peptides to the 503A Bulk Drug Substance List, despite FDA scientists recommending against all of them because of limited evidence of their safety and effectiveness.
PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.
Read More about PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply